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Abstract 1 
Background and aims: Hepatitis C virus (HCV) incidence among HIV-positive men 2 
who have sex with men (MSM) has increased since 2000, though regional 3 
differences have been documented in recent years. We aimed to 1) estimate trends 4 
in HCV incidence among HIV-positive MSM, 2) assess the association between 5 
incidence and geographical region, age and HIV-related measurements and, 3) 6 
assess temporal changes in time from HIV seroconversion to HCV infection.  7 
 8 
Methods: We used data from MSM with well-estimated dates of HIV seroconversion 9 
from the CASCADE Collaboration (1990-2014). We allowed for smoothly varying 10 
trends in HCV incidence over calendar time using restricted cubic splines. We 11 
assessed the association of calendar year, age, CD4 count (lagged), HIV RNA 12 
(lagged), geographical region and HIV infection stage (recent vs. chronic) with HCV 13 
incidence using Poisson regression. 14 
 15 
Results: Of 5,941 MSM, 337 acquired HCV during follow-up. HCV incidence 16 
significantly increased from 0.7/1000 person-years (py) in 1990 to 18/1000 py in 17 
2014. Recent calendar years, younger age, recent HIV infection and higher HIV RNA 18 
levels were significantly associated with HCV incidence, while CD4 count was not. 19 
Trends differed by geographical region; while incidence appears to have stabilized in 20 
Western Europe and remained stable in Southern Europe, it continued to increase in 21 
Northern Europe in recent years. Time from HIV to HCV infection significantly 22 
decreased over calendar time (p<0.001). 23 
 24 
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Conclusions: HCV has continued to spread among HIV-positive MSM in recent 1 
years, but trends differ by geographical region. Interventions to decrease the risk of 2 
HCV acquisition and increase early diagnosis are warranted. 3 
 4 
Lay summary: Hepatitis C virus infection continues to spread among HIV-positive 5 
men who have sex with men, especially among younger individuals. However, trends 6 
seem to differ by European region in recent years. Furthermore, men who have sex 7 
with men with a higher HIV RNA load were more likely to get infected with the 8 
hepatitis C virus. During recent HIV infection, MSM appear to be at higher risk of 9 
acquiring hepatitis C.  10 
 11 
Word count abstract: 252 12 
 13 
Keywords: Hepatitis C, incidence, HIV seroconverters, men who have sex with 14 
men, HIV RNA  15 
 16 
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Introduction 1 
 2 
Since 2000, hepatitis C virus (HCV) incidence has increased among HIV-positive 3 
men who have sex with men (MSM) [1,2]. Using data from the CASCADE 4 
Collaboration (Concerted Action on SeroConversion to AIDS and Death in Europe) in 5 
EuroCoord, we previously showed that HCV incidence increased in MSM with well-6 
estimated HIV seroconversion dates after 1990, but the main expansion of the HCV 7 
epidemic was observed from 2002 until 2007, the censoring date of the analysis [1]. 8 
A recent meta-analysis showed that HCV incidence has continued to increase, with 9 
an estimated pooled incidence of 13/1000 person-years (py) in 2010 to an 10 
extrapolated incidence estimate of 19/1000 py in 2015 [2]. However, other studies 11 
have shown varying trends in HCV incidence among MSM over the past years [3,4]. 12 
In Amsterdam, the Netherlands, HCV incidence seems to be stabilizing [3], whereas 13 
in Switzerland an increasing incidence among MSM has been observed [4]. 14 
 15 
A number of factors such as fisting, the presence of sexually-transmitted infections 16 
(STIs), use of recreational drugs, and condomless anal intercourse have been 17 
shown to be significantly associated with acute HCV infection [4-10]. In addition, one 18 
study from the US reported that older age was independently associated with an 19 
acquired HCV infection [10], whereas another study from the Netherlands reported 20 
that younger MSM had a higher risk [3]. As acute HCV infections are predominantly 21 
found among HIV-positive MSM, it has been suggested that HIV facilitates sexual 22 
transmission of HCV [11]. However, contrasting results on the association between 23 
CD4+ T-cell count (CD4 count) and HCV incidence have been reported [4,9,10,12]. 24 
Additionally, few studies have investigated the association with HIV RNA and, those 25 
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that have, either dichotomized HIV RNA and/or could only assess the association in 1 
univariable analyses [4,9,12]. The role that HIV-related factors play in the spread of 2 
HCV among HIV-positive MSM is currently still being debated.  3 
 4 
Using data among MSM with well-estimated dates of HIV seroconversion from the 5 
CASCADE Collaboration we aimed to 1) update trends in HCV incidence; overall 6 
and by geographical region, 2) assess the associations between HCV incidence and 7 
HIV-related measurements, geographical region, age and calendar year, and 3) 8 
assess whether the time interval between HIV seroconversion and HCV infection has 9 
changed over calendar time.   10 
11 
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Methods 1 
We used data from 16 out of 28 cohorts from the CASCADE Collaboration across 2 
Europe, Australia and Canada. Of the excluded cohorts, 5 were non-MSM cohorts 3 
and 6 cohorts had tested less than 50% of MSM for HCV and could not provide 4 
stored samples for HCV testing (missing HCV status data from 57.2% to 96.2%) 5 
(Fig. 1). The Kenyan cohort (IAVI; n=92) was also excluded as we believe that the 6 
HCV epidemic among MSM in Kenya differs from that in high-income countries (no 7 
incident HCV infections were observed). All cohorts include data from HIV-positive 8 
individuals with dates of HIV seroconversion that could be reliably estimated based 9 
on the midpoint between the last HIV-negative and first HIV-positive test (at most 36 10 
months apart) or, evidence of acute HIV infection. Details of CASCADE have been 11 
previously described [13]. We included only men from the 16 cohorts who were 12 
recorded as having acquired HIV through sex between men and whose potential HIV 13 
transmission route excluded injecting drug use. For all cohorts, we used all available 14 
data, except for MSM from the French PRIMO cohort who were censored at the 31st 15 
of December 2005 as routine HCV testing was only recorded until that year. All 16 
collaborating cohorts received approval from their regulatory or national ethic boards 17 
(see Appendix) and informed consent was obtained for all participants. 18 
 19 
HCV negative status throughout follow-up was based on at least one HCV-negative 20 
test result and never testing HCV positive. HCV infection was based on any positive 21 
HCV test (RNA, antibodies and/or antigen). Among MSM who acquired HCV during 22 
follow-up, the date of HCV infection was estimated as the midpoint between the last 23 
HCV-negative and first HCV-positive test. To optimize testing frequency, we 24 
performed additional HCV testing in cohorts that had stored specimens (8 cohorts). 25 
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Stored samples from HCV-negative MSM were tested using a sample closest to the 1 
date of their last clinic visit if more than 2 years had elapsed since their last HCV-2 
negative test date. For HCV-positive MSM without a previous HCV-negative test 3 
date, the sample closest to HIV seroconversion but up to one year of it was tested to 4 
assess whether they had become HCV infected during follow-up; if HCV negative, 5 
midpoint samples were tested until the HCV seroconversion interval was a maximum 6 
of 2 years. For MSM with a recorded HCV infection during follow-up but with an HCV 7 
test interval >2 years, samples with dates which fell in the interval between their last 8 
HCV-negative and first HCV-positive test date were tested. All cohorts provided a 9 
date of start of routine HCV testing (defined by testing of all MSM for HCV according 10 
to prevailing guidelines or practices) and details on HCV testing strategies (e.g., 11 
retrospective testing).  12 
 13 
HCV incidence  14 
We estimated overall HCV incidence trends between 1990 and 2014 and stratified 15 
by European geographical region between 1997 until 2013 as not all regions have 16 
available data for the total study period. Geographical region was defined based on 17 
the United Nations classification criteria [14], namely Western (the Netherlands, 18 
Switzerland, France, Austria and Germany), Northern (United Kingdom and Norway), 19 
and Southern Europe (Italy, Spain and Greece), North America (Canada) and 20 
Australia and New Zealand (Australia) (Table 1). We only illustrate HCV incidence by 21 
geographic region for the three European regions as Canada and Australia had 22 
relatively small numbers of MSM and few HCV infections were observed. MSM were 23 
considered at risk from the latest of: HIV seroconversion, routine HCV testing date 24 
per cohort or enrolment in the cohort (Table 1). We used two methods to calculate 25 
  
Manuscript - HCV incidence among HIV-positive MSM  
van Santen et al 
11
follow-up time as previously described [1]. In both methods, MSM with one or more 1 
HCV-positive tests but without a previous HCV-negative test were excluded (Fig. 1). 2 
In method 1, follow-up time began from the moment MSM were considered at risk 3 
and will likely underestimate HCV incidence as some of the excluded MSM, who only 4 
had HCV-positive tests under active follow-up, could have become infected between 5 
the moment they were considered at risk and their first HCV test. Appreciating this 6 
possible underestimation, we applied another method (method 2) where follow-up 7 
began from the first HCV-negative test after becoming at risk (i.e., left truncation). 8 
This approach, however, leads to a shorter follow-up time for MSM who remained 9 
HCV-negative throughout follow-up as they are less likely to have been tested 10 
retrospectively compared to MSM who became HCV-positive. Consequently, this 11 
method is likely to overestimate HCV incidence. In both methods follow-up was 12 
calculated until the last HCV-negative date or, in case of HCV infection, the midpoint 13 
date. Only the first observed HCV infection during follow-up within an individual was 14 
included in the analyses. We used Poisson regression models where HCV incidence 15 
was allowed to vary smoothly over calendar time using restricted cubic splines for 16 
the overall and the stratified analyses (i.e., by geographical region). We performed a 17 
sensitivity analysis using an interval-censored approach as previously described [2] 18 
(Supplementary text 1).  19 
 20 
HCV risk factor analyses 21 
We used three Poisson regression models that included calendar year using the 22 
method 1 approach to calculate follow-up. We assessed variation of HCV incidence 23 
by geographical region (model 1) and the associations with age (model 2), and HIV-24 
related measurements: CD4 count, HIV RNA and HIV infection stage (model 3). All 25 
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continuous variables were included as restricted cubic splines (calendar year, 1 
current age, log10 HIV RNA and cube root CD4 count). The knots were chosen based 2 
on the 2.5, 25, 50, 75 and 97.5 percentiles.  3 
Model 1 4 
We compared the fit of three submodels by means of the Akaike information criterion 5 
(AIC) - model 1.1=calendar year only, model 1.2=calendar year and region as main 6 
effects, model 1.3=calendar year, region, and their interaction.  7 
Model 2 8 
We then added age to the best fitting model 1. In this model, we tested the 9 
interaction between age and both region and calendar year. Significant interactions 10 
were included in this model. 11 
Model 3 12 
This multivariable model included: age, calendar year, region, HIV RNA and CD4 13 
count. The CD4 count and HIV RNA value from the previous visit were used, but had 14 
to be no more than one year before. Missing HIV RNA and CD4 count data were 15 
imputed based on individual predicted values from random-effects models adjusted 16 
for age and stratified by combination antiretroviral therapy (cART) use: treatment 17 
naïve, on cART, and during cART interruption among cART-experienced 18 
(Supplementary text 2). For this model we defined a treatment interruption as a stop 19 
of cART for >1 week. When a person had no CD4/HIV RNA values throughout 20 
follow-up, we used the predicted values based on the fixed effects. We defined cART 21 
as a 3 drug ART regimen containing 2 different classes, or 3 nucleoside reverse 22 
transcriptase inhibitors (NRTIs), provided Tenofovir or Abacavir were included in the 23 
regimen. In additional analyses we assessed whether a recent HIV infection (defined 24 
as the period from estimated HIV seroconversion to less than 0.7 years hereafter) 25 
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was associated with HCV incidence using model 3. We also tested the interaction 1 
between HIV RNA and HIV infection stage (recent vs. chronic). We used the 2 
likelihood ratio test to test significance in model 2 and 3. Instead of reporting 3 
incidence ratios, we illustrate the association between age, CD4 count and HIV RNA 4 
and incidence by plotting the absolute incidence with 95% confidence intervals, 5 
choosing representative values (e.g., median values) for the other covariates. 6 
 7 
Sensitivity analyses 8 
We performed four sensitivity analyses. As we imputed missing CD4 and HIV RNA 9 
values, first, we performed the analyses using predicted values instead of using a 10 
combination of predicted and observed values. Second, we performed a complete 11 
case analyses in which only observed values were included. Third, an analysis was 12 
performed where the antepenultimate CD4 count and HIV RNA value were used. 13 
The reason for the third analysis is that antibody development might be delayed in 14 
HIV-positive individuals [15,16] and in our study 83.4% (n=281) of HCV infections 15 
were based on HCV antibody seroconversion and 15.7% (n=53) were based on a 16 
positive HCV RNA test and an HCV-antibody negative test result. Lastly, although 17 
additional HCV testing was performed in the Italian cohort (ICoNA), we performed 18 
the overall HCV incidence analyses without this cohort as currently there is no 19 
routine HCV testing in place.  20 
 21 
  22 
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Time from HIV to HCV  1 
Kaplan-Meier curves were constructed applying the method 1 follow-up calculation to 2 
compare cumulative HCV incidences by calendar period of HIV seroconversion. We 3 
modelled whether HCV incidence depended on calendar year using a Cox 4 
proportional hazards model, including calendar year of HIV seroconversion as a 5 
continuous variable using restricted cubic splines.  6 
 7 
Statistical analyses were performed using R [17] and Stata [18] software.   8 
 9 
10 
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Results 1 
Of 17,429 HIV-positive MSM, 7,368 MSM were excluded from 6 cohorts with more 2 
than 50% missing HCV status data and that could not provide stored samples for 3 
HCV testing (Fig. 1). Of the remaining 10,061 MSM, 9,014 had at least one HCV test 4 
result of whom 8,311 tested only HCV negative and 703 had at least one HCV-5 
positive test result. MSM with HCV test results did not differ by age or ethnicity from 6 
MSM without test results, but were more likely to have a post-secondary education 7 
(37% vs. 32%). The median and mean number of HCV tests during follow-up among 8 
cohorts that routinely and prospectively collected HCV data (n=13) was 3.0 9 
(Interquartile range (IQR)=2-6) and 4.1 (Standard deviation=3.6), respectively. A 10 
total of 7,864 MSM had follow-up and at least one HCV test result (Table 1). Among 11 
these MSM, 57.0% were white and median age was 34 years (IQR=28-41) at 12 
inclusion. The median year of HIV seroconversion was 2004 (IQR=1999-2008). Over 13 
the total study period, the median observed CD4 count was 509 cells/µl (IQR=367-14 
684), median observed HIV RNA was 70
 
copies/mL (IQR=50-15522) and 70.3% 15 
started or were on cART.  16 
 17 
A total of 5,941 and 4,326 MSM were eligible according to method 1 and 2, 18 
respectively (Fig. 1;Table 1). These MSM accounted for a total of 28,600 and 19,480 19 
person-years and 337 and 279 HCV infections in method 1 and 2, respectively. The 20 
median follow-up time was 4.0 (IQR=1.7-7.2) and 3.9 (IQR=2.0-6.3) years in method 21 
1 and 2, respectively. Of the 337 incident HCV infection observed during follow-up, 22 
25 (7.4%) occurred during recent HIV infection. 23 
 24 
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HCV incidence  1 
HCV incidence significantly increased from 1990 onwards 2 
(pmethod1<0.001;pmethod2=0.04); with an estimated incidence ranging from: 0.7/1000 py 3 
(95% confidence interval (CI)=0.1-5) in 1990 to 18/1000 py (95%CI=9-37) in 2014 in 4 
method 1 and from 3/1000 py (95%CI=0.4-18) in 1990 to 21/1000 py (95%CI=10-42) 5 
in 2014 in method 2 (Fig. 2). The interval-censored method showed a similar 6 
increasing trend (Supplementary Fig. 1). Excluding one cohort (ICoNA) from the 7 
overall analyses, led to similar statistically significant increasing trends by both 8 
methods, although the estimations were slightly lower (Supplementary Fig. 2). The 9 
stratified analyses by geographical region showed that in recent years HCV 10 
incidence seems to have increased in Northern Europe, but calendar year was only 11 
statistically significant in method 2 (p=0.02) (Fig. 3). In Southern Europe, a stable 12 
trend was observed and calendar year was not significant. In Western Europe the 13 
trend was significant in both methods (pmethod1=0.001;pmethod2=0.005); based on 14 
method 1, HCV incidence increased sharply from 14/1000 py (95%CI=10-20) in 2006 15 
to 23/1000 py (95%CI=17-31) in 2009, but declined thereafter to 9/1000 py 16 
(95%CI=3-27) in 2013 (Fig. 3). 17 
 18 
HCV risk factor analyses 19 
The first analysis showed that the model with region and calendar year as main 20 
effects only (model 1.2) had the lowest AIC of the three submodels, thus the best fit. 21 
The second model showed that younger HIV-positive MSM had a higher risk of HCV 22 
infection (p=0.005) (Fig. 4A). The interaction term between age and region was 23 
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borderline significant (p=0.05). Based on the model with the interaction term, in 1 
Western Europe, HCV incidence remained highest and stable until around age 35 2 
and declined thereafter (Supplementary Fig. 3). In Northern and Southern Europe, 3 
HCV incidence increased until age 35, and declined thereafter.  4 
In the third model, a higher HIV RNA was associated with higher HCV incidence 5 
(p=0.001) (Fig. 4C), especially when log10 HIV RNA was ≥5 copies/mL, whereas 6 
CD4 count (Fig. 4B) was not (p=0.53). When we added “HIV infection stage” to the 7 
model, the association between HIV RNA and HCV incidence was attenuated 8 
(p=0.01) (Fig. 4D). HCV incidence was higher during recent HIV infection than during 9 
chronic HIV infection (Incidence Rate Ratiorecent vs. chronic=1.8, 95%CI=1.1-2.7, 10 
p=0.02). The interaction term between HIV infection stage and HIV RNA was not 11 
significant (p=0.60), and was left out of the model. The association with CD4 count 12 
remained non-significant (p=0.53).  13 
 14 
Sensitivity analyses 15 
All sensitivity analyses showed comparable associations of HIV RNA, CD4 count 16 
and calendar year with HCV incidence and the conclusions were not altered. 17 
However, in the complete case analyses, HIV RNA was non-significant (p=0.25) 18 
(Supplementary Fig. 4).  19 
In the model that included HIV infection stage, two sensitivity analyses (i.e., 20 
antepenultimate and predicted values) showed comparable associations between 21 
HIV RNA and HCV incidence, but when antepenultimate HIV RNA values were used, 22 
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the association was no longer statistically significant (p=0.09). In the complete case 1 
analyses, there was no association (p=0.40).  2 
 3 
Time from HIV to HCV  4 
Among 5,680 MSM who seroconverted for HIV at or after 1990, median time from 5 
HIV seroconversion to HCV infection was 5.2 years. The time from HIV 6 
seroconversion until HCV infection significantly decreased over calendar periods 7 
(plog-rank<0.001). At 3 years after HIV seroconversion, the cumulative HCV incidence 8 
was 5.9% (95%CI=3.8-9.2%) in 2010-2014 compared to 2.0% (95%CI=0.5-7.8%) in 9 
1990-1994 (Fig. 5). The Cox model showed that MSM who seroconverted for HIV in 10 
2010, had a 6.1 (95%CI=2.8-13.3) times higher hazard of acquiring HCV than MSM 11 
who seroconverted in 1990 (p<0.001) (Supplementary Fig. 5).  12 
13 
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Discussion 1 
Using data from the CASCADE Collaboration among HIV-positive MSM with well-2 
estimated dates of HIV seroconversion, we showed that HCV incidence significantly 3 
increased from 1990 onwards and no decline was observed in recent years. This 4 
suggests on-going transmission of HCV among HIV-positive MSM. However, trends 5 
seem to differ by geographical region. While HCV incidence appears to have 6 
stabilized in Western Europe and remained stable in Southern Europe, a recent 7 
increase in HCV incidence was observed in Northern Europe. Interestingly, higher 8 
HIV RNA levels, recent HIV infection and younger age were associated with higher 9 
HCV incidence. The time from HIV seroconversion to HCV infection has significantly 10 
shortened in recent years. Hence, routine and continued surveillance following HIV 11 
diagnosis is needed.  12 
  13 
The increasing trend in HCV incidence over time is comparable with the trend 14 
observed in a recent meta-analysis [2]. We estimated that in 2014 HCV incidence 15 
was between 18 and 21/1000 py and in the meta-analysis the extrapolated estimate 16 
was 19/1000 py in 2015 [2]. A recent study from EuroSida, not restricted to HIV 17 
seroconverters, also reported that HCV incidence differed by European geographical 18 
region; Eastern, Northern and Southern Europe had higher odds for HCV 19 
seroconversion than Western Europe [19]. Interestingly, no HCV infections were 20 
observed among MSM from the Kenyan cohort, while another Kenyan study reported 21 
that 10% (30/300) of HIV-positive male and female patients were HCV-coinfected 22 
[20]. This might suggest that HCV has not yet been introduced in the Kenyan MSM 23 
population. The decline in HCV incidence that we observed after 2009 in Western 24 
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Europe might be ascribed to earlier introduction or recognition of HCV. 1 
Consequently, as previously suggested [3], this might have led to a saturation effect 2 
among MSM at higher risk for HCV infection and/or increased HCV awareness, 3 
leading to more HCV testing and treatment, as well as safer-sex practices. 4 
Conversely, since the introduction of cART, condom use has decreased over time 5 
among MSM [21,22], which probably led to the increase in syphilis incidence across 6 
European countries in recent years, especially among HIV-positive MSM [23]. In 7 
Northern Europe (UK and Norway) HCV incidence seems to have increased in 8 
recent years, although the overall effect of calendar year was only significant when 9 
method 2 was used. An European survey in 2010 among MSM showed that the 10 
prevalence of drug use associated with ‘chemsex’ – i.e., drug use to enhance sexual 11 
arousal [24] – was highest in three UK cities [25]; as injecting and non-injecting drug 12 
use have been associated with acute HCV among HIV-positive MSM [6,8-10], 13 
differences in HCV trends might be partly explained by differences in drug use 14 
across European countries. However, we cannot discern whether that study is 15 
representative for MSM across Europe. Given the overall continued rise of HCV 16 
incidence, HCV-treatment guidelines should consider recommending direct-acting 17 
antivirals during acute HCV infection - when registered [26] - to prevent on-going 18 
transmission. As suggested by modelling studies, the greatest population benefit 19 
among HIV-positive MSM can be achieved when HCV treatment is provided within 1 20 
year of HCV diagnosis, together with behavioural interventions [27, 28].  21 
 22 
Furthermore, we found that younger MSM, peaking at around age 35, are at higher 23 
risk for HCV infection, in line with findings from the Netherlands [3] but in contrast to 24 
a study in the USA, where older MSM had a higher risk of HCV infection [10]. 25 
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Regional differences in the HCV epidemic among HIV-positive MSM could explain 1 
this discrepancy, in line with our finding of a borderline significant interaction 2 
between age and region.  3 
 4 
HIV RNA was significantly associated with HCV incidence, especially when log10 HIV 5 
RNA was ≥5 copies/mL. Few studies have assessed the association between HIV 6 
RNA and HCV incidence [4,9,12] and, to the best of our knowledge, this is the only 7 
study to have modelled HIV RNA as a continuous variable in multivariable analysis. 8 
In univariable analyses, two observational cohort studies [4,9] found a significant 9 
association between HIV RNA with HCV incidence, whereas a clinical HIV cohort did 10 
not [1]. Although, in the Swiss Cohort study, this association was no longer 11 
significant in multivariable analysis [4]; but ART use was included in that 12 
multivariable model which may mask the effect of HIV RNA as it may lie on the 13 
causal pathway. However, in our study, the association between HIV RNA and HCV 14 
incidence was attenuated when HIV infection stage was included in the model. The 15 
overlap in risk behaviour between HIV and HCV might result in the acquisition of 16 
both viruses simultaneously. We found that HCV infection is more likely during 17 
recent HIV infection and this is a period characterized by high HIV RNA levels, which 18 
might explain the stronger association between HCV incidence and HIV RNA when 19 
HIV infection stage is not included in the model. Additionally, until recently, these 20 
individuals might not be on cART. Our finding underscores the importance of 21 
monitoring HCV incidence and risk factors among HIV seroconverters. 22 
Yet HIV RNA remained statistically significant. HIV RNA might partly explain why 23 
HIV-positive MSM have a higher risk of HCV infection than HIV-negative MSM [11]. 24 
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The biological mechanism behind the association with HIV RNA may be through the 1 
activation of Langerhans cells (LCs) that results in the facilitation of HCV 2 
transmission, as immature LCs capture but do not transmit HCV, while activated LCs 3 
(due to HIV replication) are able to transmit the virus [29]. Alternatively, having an 4 
STI, a risk factor for HCV infection [4,6,9,10,12] leads to an increase in HIV RNA 5 
levels [30]. In that case, HIV RNA would be merely a proxy for having an STI. Also, 6 
higher HIV RNA levels might be surrogate for poor adherence to cART. 7 
Unfortunately, we could not assess the effect of STIs and cART adherence on HCV 8 
incidence, as most cohorts do not collect these data.  9 
 10 
We found no association between HCV incidence and CD4 count, which is in line 11 
with most studies [3,4,6,12]. However, one showed that HIV-positive MSM with lower 12 
CD4 counts had a higher risk of acquiring HCV [9] while another study only found an 13 
association with CD4 count below 500 cell/µl [10]. However, both studies did not 14 
exclusively include HIV seroconverters and did not account for time since HIV 15 
infection.  16 
 17 
A previous study using data from the CASCADE Collaboration and the same 18 
estimating procedures, reported a similar increasing trend in HCV incidence until 19 
2007 [1]. However, HCV incidence in 2007 using method 2 was considerably higher 20 
than our estimation (51/1000 vs. 21/1000 py); although confidence intervals were 21 
wide after 2005 and our estimates fall within this confidence intervals previously 22 
estimated [1]. The present study provides a more accurate estimate of HCV 23 
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incidence after 2000 as additional HCV testing was performed to minimize bias 1 
related to selective testing and more MSM were included.  2 
 3 
Our study has some limitations. First, as HCV infection was based on any kind of 4 
HCV test, an observed HCV infection might be a re-infection; although 99.1% 5 
(334/337) of HCV infections in our study were based on HCV-antibody 6 
seroconversion or evidence of acute/recent primary HCV infection. Also, since we 7 
lacked data on the mode of HCV transmission, we could not assess whether all HCV 8 
infections were sexually transmitted and whether changes in risk behaviour over time 9 
(e.g., increase in injecting drug use (IDU)) are driving the HCV epidemic. However, 10 
studies have reported HCV acquisition in the absence of traditional HCV risk factors, 11 
such as IDU, in the majority of MSM [4,5,7-10,12]. Hence, the increase in sexual risk 12 
behaviour among MSM (e.g, condomless anal intercourse [21]) is likely to partly 13 
explain the observed trends. Furthermore, although recreational drug use is common 14 
among MSM [25], recent studies have reported a low percentage of IDU among HIV-15 
positive MSM with acute HCV infection (5.8% and 12.2%) [6,9]. To the best of our 16 
knowledge, evidence of an increase in IDU is scarce as only one study assessed 17 
trends in recent years; an increase in IDU, from 45.1% in 2005 to 53.8% in 2014, 18 
was observed among HIV-positive MSM reporting methamphetamine use in 19 
Australia [31]. Further research is needed to assess changes over time in HCV-20 
related risk factors and the proportion of HCV acquisition attributable to sexual 21 
practices and drug use among MSM. Despite the lack of behavioural data, the main 22 
focus of our study was to assess temporal trends in HCV incidence, irrespective of 23 
the mode of HCV transmission. Furthermore, it is important to bear in mind that 24 
clinicians may have monitored patients at risk for HCV infection better over time, 25 
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leading to more HCV-positive test results in recent years. To account for this 1 
possible bias we performed additional HCV testing and we only included data from 2 
the date of routine testing onwards. However, the median and mean number of tests 3 
was 3 and 4, respectively, over a median follow-up time of 4 years, suggesting that 4 
current guidelines [32] might not be followed consistently. This is in line with results 5 
from EuroSida where only a median of 3 tests were performed per patient between 6 
2002 and 2013 [19]. In addition, due to a lack of country specific HCV testing 7 
guidelines (e.g., Italy), HCV testing practices may not be systematic.  8 
 9 
The strengths of our study are that we had data from HIV seroconversion onwards 10 
for a large group of MSM, and extensive follow-up that enabled us to assess 11 
temporal changes in time from HIV seroconversion to HCV infection and the 12 
association between HCV incidence and HIV infection stage. We also applied 13 
different estimating methods to calculate HCV incidence and various sensitivity 14 
analyses. All methods showed comparable results suggesting that our results are 15 
robust.  16 
 17 
To conclude, no decline in HCV incidence was observed in recent years, although 18 
trends seem to differ by geographical region. Hence, HCV screening among HIV-19 
positive MSM should be continued and routinely and frequently offered. Furthermore, 20 
targeted preventive measures should be implemented and/or scaled-up to decrease 21 
the risk of HCV acquisition. Other than recent calendar year, younger age, recent 22 
HIV infection and high HIV RNA levels were all associated with HCV incidence.  23 
24 
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Figures titles and legends 1 
Fig. 1: Flow diagram of the study population selection for method 1 and 2 of 2 
the HCV incidence analyses  3 
* Becoming at risk being the latest of: enrolment in the cohort, routine HCV testing 4 
date per cohort or HIV seroconversion. 5 
** MSM from the French Primo cohort were censored at the 31st of December 2005 6 
as HCV testing was only systematically recorded until that year. 7 
The grey boxes depict MSM whose data were excluded from the analyses. 8 
 9 
Fig. 2: HCV incidence among HIV-positive MSM using two methods to estimate 10 
follow-up in the CASCADE Collaboration; 1990-2014 11 
Method 1: dashed line, 95%CI: dashed area. Method 2: solid line, 95%CI: grey solid 12 
area.  13 
Poisson regression was used to test the overall effect of calendar year on HCV 14 
incidence between 1990 and 2014.  15 
 16 
Fig. 3: HCV incidence among HIV-positive MSM by European UN geographical 17 
region in the CASCADE Collaboration; 1997-2013 18 
Abbreviations: m1= method 1; m2= method 2 19 
Method 1: dashed line, 95%CI: dashed area. Method 2: solid line, 95%CI: grey solid 20 
area.  21 
P-values: overall effect of calendar year on HCV incidence between 1997 and 2013 22 
obtained from Poisson regression models.  23 
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Fig. 4. HCV incidence by age, CD4 cell count and HIV RNA among HIV-positive 1 
MSM from the CASCADE Collaboration, in year 2007 in Western Europea 2 
 3 
4(A). Incidence by age in years (model 2)b 4 
4(B). Incidence by CD4 count for an individual with a HIV RNA = 1000, aged 35 5 
(model 3) 6 
4(C). Incidence by HIV RNA for an individual with a CD4 cell count = 500, aged 35 7 
(model 3) 8 
4(D). Incidence by HIV RNA for an individual with a HIV RNA = 1000, aged 35, in the 9 
chronic HIV infection stage (model 3) 10 
 11 
a
 The relative hazards obtained from the regression models were translated into the 12 
predicted incidence and this is illustrated for certain values of the covariates (e.g., 13 
only for Western Europe). 14 
b Obtained from model 2 without the interaction term between age and region. 15 
 16 
Fig. 5: Time from HIV seroconversion until HCV infection over time: Kaplan-17 
Meier curves by calendar period of HIV seroconversion in the CASCADE 18 
Collaboration (1990-2014)a 19 
a
 Curves were truncated when less than 10 individuals were at risk for HCV infection.  20 
The log-rank test was used to assess changes in the time from HIV seroconversion 21 
to HCV infection among calendar periods.  22 
  23 
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Cohorts At least 
one HCV 
test 
result 
MSM 
with 
follow-
upa & at 
least 
one HCV 
test 
result 
At-risk 
setb 
Start 
routine 
testing 
date 
     
   _HCV+d_ _HCV-e __Method 
1__ 
__Method 
2__ 
   
Nc n (%) Total, n 
(%) 
n (%) n (%) n HCVsc - 
Pys 
n HCVsc - 
Pys 
 
Southern 
Europe 
         
AMA; 
n=177 
172 
(97.2%) 
167 
(94.4%) 
2 (1.2%) 165 
(98.8%) 
128 0 - 526.3 87 0 - 347.2 1-1-1991 
COR; 
n=365 
353 
(97.7%) 
310 
(84.9%) 
5 (1.6%) 302 
(97.4%) 
184 3 - 246.2 68 3 - 87.7 1-1-2005f 
ICO; 
n=1018 
914 
(89.8%) 
848 
(83.3%) 
49 (5.8%) 770 
(90.8%) 
497 29 - 
1926.3 
411 29 - 
1705.7 
AT 
MAD; 
n=342 
308 
(90.1%) 
293 
(85.7%) 
16 (5.5%) 274 
(93.5%) 
213 3 - 1047.9 30 3 - 56.8 1-1-1993 
VAL; 
n=165 
89 
(53.9%) 
85 
(51.5%) 
13 
(15.3%) 
71 
(83.5%) 
65 1 - 66.9 2 1 - 2.9 1-1-1998 
Total; 
n=2067 
1,836 
(88.8%) 
1,703 
(82.4%) 
85 (5.0%) 1,582 
(92.9%) 
1,087 36 - 
3813.6 
598 36 - 
2200.4 
 
Western 
Europe 
         
AQU; 
n=788 
730 
(92.6%) 
707 
(89.7%) 
29 (4.1%) 657 
(92.9%) 
486 21 - 
3053.1 
360 19 - 
2389.3 
1-1-1991 
AUS; 
n=212 
206 
(97.2%) 
201 
(94.8%) 
3 (1.5%) 193 
(96.0%) 
181 5 - 682.3 150 4 - 575.7 1-1-2006 
GER; 
n=1912 
1,848 
(96.7%) 
1,543 
(80.7%) 
63 (4.1%) 1,393 
(90.3%) 
1,025 87 - 
4557.0 
764 51 - 
2665.5 
RT 
LYO; 
n=62 
60 
(96.8%) 
59 
(95.2%) 
1 (1.7%) 57 
(96.6%) 
11 1 - 40.2 0 0 - 0 1-1-1999f 
NEM; 
n=239 
239 
(100%) 
239 
(100%) 
2 (0.8%) 215 
(90.0%) 
224 22 - 
1841.6 
144 21 - 
1098.1 
RT 
PRI; 
n=966 
894 
(92.5%) 
401 
(41.5%) 
15 (3.7%) 381 
(95.0%) 
211 6 - 791.8 190 5 - 748.5 1-1-1996f 
SWI; 
n=343 
338 
(98.5%) 
320 
(93.3%) 
4 (1.3%) 294 
(91.9%) 
274 22 - 
1532.6 
236 17 - 
1210.2 
1-1-2000 
Total; 
n=4522 
4,315 
(95.4%) 
3,470 
(76.7%) 
117 
(3.1%) 
3,190 
(91.9%) 
2,412 164 - 
12498.5 
1,844 117 - 
8687.4 
 
Northern 
Europe 
         
NOR; 
n=383 
378 
(98.7%) 
349 
(91.1%) 
10 (2.9%) 328 
(94.0%) 
305 11 - 
2165.9 
258 11 - 
1489.6 
1-1-1995 
UKR; 
n=2714 
2,209 
(81.4%) 
2,073 
(76.4%) 
50 (2.4%) 1,903 
(91.8%) 
1,937 120 - 
9395.2 
1,582 110 - 
6871.6 
1-1-2004 
Total; 
n=3097 
2,587 
(83.5%) 
2,422 
(78.2%) 
60 (2.5%) 2,231 
(92.1%) 
2,242 131 - 
11561.1 
1,840 121 - 
8361.2 
 
North 
America 
         
SAL; 
n=138 
138 
(100%) 
131 
(94.9%) 
4 (3.1%) 122 
(93.1%) 
67 5 - 327.2 43 4 - 230.0 1-1-2000 
Australia          
PHA; 
n=145 
138 
(95.2%) 
138 
(95.2%) 
5 (3.6%) 132 
(95.7%) 
133 1 - 399.4 1 1- 0.8 1-1-2002 
Total; 
n=9,969 
9,014 
(90.4%) 
7,864 
(78.9%) 
271 
(3.4%) 
7,257 
(92.3%) 
5,941 337- 
28599.9 
4,326 279 - 
19479.8 
  
 1 
Table 1: Number of MSM per cohort with and without HCV test results in the CASCADE 2 
Collaboration  3 
 4 
Abbreviations: N=number; n=number; HCVsc=HCV seroconverters; PYs=person years of 5 
observation; HCV+=HCV-positive; HCV-=HCV-negative; RT=retrospective testing; AT=additional 6 
testing only (no routine testing); AMA= AMACS cohort, Greece; AQU: Aquitaine cohort, France; AUS: 7 
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Austrian HIV cohort study, Austria; COR=CoRis cohort, Spain; GER=German cohort, Germany; 1 
IAV=IAVI, Kenya; ICO=ICONA cohort, Italy; LYO= Lyon cohort, France; MAD=Madrid cohort, Spain; 2 
NEM=Amsterdam Cohort Study among MSM, the Netherlands; NOR=Oslo and Ulleval hospital 3 
cohorts, Norway; PHA=PHAEDRA cohort, Australia; PRI=PRIMO cohort, France; SAL=Southern 4 
Alberta Clinic, Canada; SWI=Swiss HIV cohort, Switzerland; UKR=UK Register of HIV 5 
seroconverters, UK; VAL=Valencia cohort, Spain; NA=not applicable. 6 
a
 MSM with a clinic visit, and thus follow-up, after becoming at risk, being the latest of: enrolment in 7 
the cohort, HIV seroconversion or routine testing per cohort. HCV test results irrespective of the 8 
moment of becoming at risk.  9 
b
 MSM included in the analyses from 1990 until 2014. 10 
c
 Number of MSM per cohort irrespective of the moment of becoming at risk, HCV test, year and 11 
length of follow-up. 12 
d
 HCV-positive MSM without a previous HCV negative test result (i.e., excluding HCV seroconverters).  13 
e
 MSM who remained HCV negative throughout follow-up (from becoming at risk until last clinic visit). 14 
d,e Out of all MSM with follow-up & at least one HCV test result (third column). 15 
f
 Start of routine testing date before individuals were enrolled in the cohort. 16 
 17 
  
17,429 MSM from 
23 cohorts that 
included MSM out 
of 28 cohorts 7,368 MSM 
excluded (6 
cohorts), no stored 
samples available 
and >50% missing 
HCV status
10,061 MSM in 17 
cohorts
9,014 MSM with at 
least one HCV test 
result in 16 
cohorts
7,864 MSM with 
HCV test results 
and follow-up
7,593 MSM
995 MSM without 
HCV test results 
and 92 MSM from 
IAVI (Kenya)
661 without follow-
up after becoming 
at risk* and
489 PRIMO MSM 
censored**
271 HCV+ MSM 
without a previous 
HCV- result 
5,953 MSM
1,640 last HCV 
negative test 
before becoming 
at risk*
4,384 MSM with at 
least two HCV test 
results
5,941 MSM in 
method 1 
analysis
4,326 MSM in 
method 2 
analysis
12 MSM without 
follow-up after 
1990
1,569 only one 
HCV test result 
after becoming at 
risk for method 2
58 first HCV test 
result during 
follow-up was 
positive 
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On-going hepatitis C virus transmission among HIV-
positive men who have sex with men (MSM) 
Younger age, recent HIV infection and higher HIV RNA 
levels were significantly associated with HCV incidence, 
while CD4 was not  
Recent HCV trends differ by European region 
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